Generica İlaç Expands Its Portfolio

Generica Pharma, one of the fastest-growing companies in the pharmaceutical sector in recent years with a broad product portfolio comprising original, generic and OTC drugs in acute and chronic markets, has announced that it has signed a contract to acquire one of Novartis's two manufacturing facilities located in Gebze.

"This acquisition will accelerate our process of continuously bringing new products to the Turkish market"

Generica Pharma Chairman and Founder Alp Karaağaç is a member of a family that has been part of the Turkish pharmaceutical industry for 60 years. Karaağaç emphasised that with this acquisition, they aim to add new generic and OTC products to their portfolio and market: "We are at the stage of taking over manufacturing operations at one of the production facilities from global pharmaceutical leader Novartis. We are pleased to incorporate an excellent production facility with an expert team that will take Generica to the next level. This acquisition will bring high-quality production that meets and even exceeds the expectations of all our stakeholders. After this stage, we will continue production with factory employees in a good working environment and provide job opportunities to the younger generation. We will also add significant value to Turkish pharmaceutical R&D. Our most important objective is to continue sustainable excellence in production with this facility that meets global quality standards and to produce for many countries, particularly Europe. This business cooperation and technology transfer with a global leader like Novartis is a major gain for the Turkish pharmaceutical sector." he said. "During the planned transfer of our production facility, our top priority has been the employment of our employees and the continuity of the production process" Novartis Group Turkey President Dr. Altan Demirdere also commented on the planned divestiture of the manufacturing facilities: "We are consolidating our current 4 manufacturing facilities in Turkey and reducing them to 2. Our aim here is to increase our efficiency. Our total production and exports at our facilities in Turkey will continue to increase in the coming years. As Novartis, our priority is our responsibility to our patients, employees and the society in which we operate. With the Gebze production facility equipped with Solid, Pellet, HGC, Semi-Solid, Liquid and Suppository technologies in Turkey, Generica will continue production and supply for Novartis, which exports to 67 countries including the EU, Japan, Canada and Australia, and will continue to provide uninterrupted pharmaceuticals to health systems and patients worldwide." he stated. Alp Karaağaç noted that following the transfer, they will invest in the facility to optimise production and expand the customer base, pursuing business development opportunities and focusing on exports: "Following the completion of the transfer, we aim for a seamless transition for employees, patients, customers, business partners and all other stakeholders." he said.